Paclitaxel, a widely used chemotherapeutic agent, often induces painful
peripheral neuropathy and at present no effective
drug is available for treatment of the serious side effect. Here, we tested if intragastrical application of
bulleyaconitine A (BLA), which has been approved for clinical treatment of
chronic pain in China since 1985, could relieve the
paclitaxel-induced
neuropathic pain. A single dose of BLA attenuated the
mechanical allodynia,
thermal hyperalgesia induced by
paclitaxel dose-dependently. Repetitive administration of the
drug (0.4 and 0.8 mg/kg, t.i.d. for 7 d) during or after
paclitaxel treatment produced a long-lasting inhibitory effect on
thermal hyperalgesia, but not on
mechanical allodynia. In consistency with the behavioral results, in vivo electrophysiological experiments revealed that spinal synaptic transmission mediated by C-fiber but not A fiber was potentiated, and the magnitude of long-term potentiation (LTP) at C-fiber synapses induced by the same high frequency stimulation was ~50% higher in
paclitaxel-treated rats, compared to the naïve rats. Spinal or intravenous application of BLA depressed the spinal LTP, dose-dependently. Furthermore, patch clamp recordings in spinal cord slices revealed that the frequency but not amplitude of both spontaneous excitatory postsynaptic current (sEPSCs) and miniature excitatory postsynaptic currents (mEPSCs) in lamina II neurons was increased in
paclitaxel-treated rats, and the superfusion of BLA reduced the frequency of sEPSCs and mEPSCs in
paclitaxel-treated rats but not in naïve ones. Taken together, we provide novel evidence that BLA attenuates
paclitaxel-induced
neuropathic pain and that depression of spinal LTP at C-fiber synapses via inhibiting presynaptic transmitter release may contribute to the effect.